Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Abeona Therapeutics Inc.

< Previous 1 2 Next >
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
Abeona Therapeutics Announces Progress Update on Pz-cel Biologics License Application (BLA)
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
Abeona Therapeutics Announces $50 Million Credit Facility
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
Abeona Therapeutics Announces FDA Accepts and Grants Priority Review for Pz-cel Biologics License Application (BLA)
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
Abeona Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Developments
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
Abeona Therapeutics Submits Biologics License Application to U.S. FDA Seeking Priority Review and Approval of EB-101 for the Treatment of Patients with Recessive Dystrophic Epidermolysis Bullosa
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
Abeona Therapeutics Appoints Madhav Vasanthavada, Ph.D., M.B.A. as Chief Commercial Officer
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
Abeona Therapeutics Announces Participation in Upcoming Investor Conferences
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
Abeona Therapeutics Announces Positive Pre-BLA Meeting with FDA for EB-101 and Plans for BLA Submission
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
Abeona Therapeutics Reports Second Quarter 2023 Financial Results
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
Abeona Therapeutics Announces Submission of Briefing Package for Pre-Biologics License Application (BLA) Meeting with FDA in August 2023
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
Abeona Therapeutics Joins Rare Disease Company Coalition
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
Abeona Therapeutics Announces Closing of $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
Abeona Therapeutics Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
Abeona Therapeutics Announces Regulatory Update on Biologics License Application (BLA) for EB-101
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
Abeona Therapeutics to Present at the Jefferies Healthcare Conference
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
Abeona Therapeutics Announces Date Change for First Quarter 2023 Portfolio Update Conference Call to May 24, 2023
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
Abeona Therapeutics Announces New Preclinical Data from its AAV Ophthalmology Program at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
Abeona Therapeutics Reports First Quarter 2023 Financial Results
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
Abeona Therapeutics Announces Additional Phase 3 VIITAL™ Study Results for EB-101 Presented at the International Societies for Investigative Dermatology 2023 Meeting
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
Abeona Therapeutics Announces Multiple Abstracts Accepted from its AAV Ophthalmology Program at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
Abeona Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
Abeona Therapeutics Announces New Employee Inducement Grants
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
Abeona Therapeutics Announces Acceptance of Abstract on EB-101 Phase 3 VIITAL™ Study Results for Oral Presentation at International Societies for Investigative Dermatology (ISID) 2023 Meeting
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
Abeona Therapeutics Announces Update on AAV Ophthalmology Program
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
Abeona Therapeutics Reports Third Quarter 2022 Financial Results
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
Abeona Therapeutics Announces $35 Million Private Placement Financing
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
Abeona Therapeutics Announces Positive Topline Results with Both Co-Primary Endpoints Met in Pivotal Phase 3 VIITAL™ Study of EB-101
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.